Long-term Treatment withGalcanezumab in 29 Patients with Chronic Migraine: Resultsfrom the 3-year Continued Access Program of the REGAIN Study

Authors
Category Primary study
JournalNeurology
Year 2022
This article has no abstract
Epistemonikos ID: 834debab3a33b7c680cbac8c30da18fbfd64c059
First added on: Feb 14, 2025